FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Open Access
- 11 October 2012
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (1) , 56-59
Abstract
FMS‐like tyrosine kinase III (FLT3) mutations occur in one‐third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. FLT3 mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had FLT3‐ITD mutation and 3 had FLT3‐tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3‐mutated MDS patients was 19.0 months versus 16.4 months for FLT3‐nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3%) CMML patients: 8 had FLT3‐ITD mutation and 5 had FLT3‐TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3‐mutated CMML patients was 10.8 months versus 21.3 months for FLT3‐nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome. Am. J. Hematol. 2013.Keywords
This publication has 31 references indexed in Scilit:
- Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?Seminars in Oncology, 2011
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activationBlood, 2009
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewBritish Journal of Haematology, 2007
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significanceBritish Journal of Haematology, 2006
- Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic PotentialCell, 2005
- Internal tandem duplication offms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndromeCancer, 2004
- Internal tandem duplication and Asp835 mutations of the FMS‐like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemiaCancer, 2003